BRAF mutation predicts survival after immunotherapy across multiple cancer types

Submit Time: 2020-07-21

Author: Ge, Weiting 1 ; Cai, Wen 1,2 ; Wu, Dehao 1 ; Hu, Wangxiong 1 ; Han, Weidong 3 ; Zheng, Shu 1 ; Hu, hanguang 1,4 ;

Institute: 1.Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China; 2.Department of Gastroenterology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China; 3.Department of Medical Oncology, Biomedical Research Center, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China; 4.Department of Medical Oncology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China;

Abstracts

Recently studies in selected tumors suggested that BRAF mutation may associates with survival benefit from immune checkpoint inhibitor (ICI) therapy. To broadly investigate this association at a pan-cancer level, we analyzed two independent ICI treatment cohorts (MSKCC: n = 1630, and Dana-Farber: n = 249). BRAF-mutant patients exhibit better overall survival in the MSKCC cohort (Hazard ratio [HR] = 0.55, 95% confidence interval [CI]: 0.43-0.72; P <.001) and the result is validated by the Dana-Farber cohort (HR = 0.68, 95% CI: 0.46-0.99; P = .045). A multivariate analysis adjusting tumor mutational burden, mismatch repair status, cancer type, age and sex confirmed the results (adjusted HR = 0.58, 95% CI = 0.43-0.78; P < .001). Immunogenomic features analysis of TCGA dataset indicated that patients may respond to immunotherapy in various mechanisms. This finding substantially improve the therapeutic prospects for a sizeable fraction of patients who benefit from immunotherapy.

Download

Comment Hits:1390 Downloads:99

From: 葛维挺

Subject: Medicine, Pharmacy >> Clinical Medicine

DOI：10.12074/202007.00041

Keywords: Immunotherapy; Predictive marker; BRAF;

Cite as: chinaXiv:202007.00041 (or this versionchinaXiv:202007.00041V1)

Recommended references： Ge, Weiting,Cai, Wen, Wu, Dehao,Hu, Wangxiong,Han, Weidong,Zheng, Shu,Hu, hanguang.(2020).BRAF mutation predicts survival after immunotherapy across multiple cancer types.[ChinaXiv:202007.00041] (Click&Copy)